Is There Validity in Propensity Score–Matched Estimates of Adjuvant Chemotherapy Effects for Patients With Rectal Cancer?
Author:
Affiliation:
1. Surgical Oncology, Health Services Research, University of Texas MD Anderson Cancer Center, Houston
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Reference16 articles.
1. Rectal Cancer, Version 2.2015.;Benson;J Natl Compr Canc Netw,2015
2. Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection;Dossa;JAMA Oncol
3. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection;Polanco;JAMA Oncol
4. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.;Breugom;Ann Oncol,2015
5. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT).;Sainato;Radiother Oncol,2014
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis;Frontiers in Oncology;2022-12-16
2. Benefit or bias: Using retrospective databases to evaluate efficacy of cancer treatments;Colorectal Disease;2022-08
3. Evaluating the benefit of adjuvant chemotherapy in patients with ypT0–1 rectal cancer treated with preoperative chemoradiotherapy;World Journal of Gastrointestinal Surgery;2021-09-27
4. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection;British Journal of Cancer;2020-07-29
5. Insurance Status as a Surrogate for Social Determinants of Health in Cancer Clinical Trials;JAMA Network Open;2020-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3